2026-01-04 - Analysis Report
Okay, let's break down the information about Merck & Co. Inc. (MRK).

**1) Return Rate Comparison & Alpha/Beta Analysis**

*   **Company Overview:** Merck & Co. Inc. is a global pharmaceutical company focused on developing and marketing medicines and vaccines.
*   **Return Rate Comparison:** MRK's cumulative return (22.93%) significantly underperforms the S&P 500 (91.00%). The divergence is -68.07%.  This divergence is relatively low, placing it towards the lower end of its historical range.
*   **Alpha/Beta Analysis:**
    *   **Alpha:** The Alpha fluctuates considerably. While some periods show strong positive Alpha (outperformance relative to market risk), recent years have negative Alpha, indicating underperformance. The recent Alpha is -86.0%.
    *   **Beta:**  The Beta has decreased over the years, going from 0.7 to 0.3. This indicates that MRK's price movement has become less correlated with the market. It used to move roughly 70% as much as the market, but now it moves only 30% as much.
    *   **CAGR and MDD:** MRK has experience a low CAGR and high MDD recently, indicating the stock had a negative growth trend.
    *   **Cap:** MRK has a market capitalization over 200 billion.

**2) Recent Stock Price Fluctuations**

*   **Current Price:** \$106.45
*   **Recent Movement:** Up slightly from the previous close (+$1.13).
*   **Moving Averages:**
    *   5-day SMA: \$106.23
    *   20-day SMA: \$102.01
    *   60-day SMA: \$94.48

**Analysis:** The stock is trading above all its moving averages, suggesting a short-term uptrend. The 5-day SMA being very close to the current price implies recent stability. The larger gap between the current price and the 60-day SMA indicates a stronger upward trend over the past two months.

**3) Indicators Analysis**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment Recommended).
*   **RSI:** 75.58 (Overbought).  An RSI above 70 is often considered overbought, suggesting the stock may be due for a pullback.
*   **PPO:** 0.0841 (Positive). The PPO is positive and is above the zero line and indicates that the shorter-term moving average is above the longer-term moving average, confirming the upward trend.
*   **Hybrid Signal:** `cash_0%_Buy 90% of cash (8 shares - Safe - MRI:0.80) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2026-01-02)` This suggest that it is relatively safe to buy at the time point.
*   **Recent Divergence Change:** 1.5 (+): Suggests a short-term increase in relative divergence.
*   **Expected Return:** -29.1%.  This is a significant negative expected return, indicating potential underperformance compared to the S&P 500 over the long term.

**4) Recent News & Significant Events**

*   **Mixed Sentiment:**  The news headlines present a mixed picture.
    *   Positive: Morgan Stanley raised their price target, Financiere des Professionnels increased their holdings, and one article suggests MRK is undervalued.
    *   Negative: One article notes a 3% stock drop, and another compares MRK unfavorably to Pfizer.

**4-2) Analyst Opinions**

*   **Consensus:**  The analyst consensus is leaning towards "Buy" (1.90).
*   **Target Price:**  The average target price is \$110.04, suggesting some potential upside from the current price.
*   **Recent Changes:** The rating changes are not mentioned.

**5) Recent Earnings Analysis**

| 날짜         | EPS  | 매출        |
|--------------|------|-------------|
| 2025-11-05   | 2.32 | 17.28 B\$   |
| 2025-08-05   | 1.76 | 15.81 B\$   |
| 2025-05-02   | 2.01 | 15.53 B\$   |
| 2024-11-06   | 1.25 | 16.66 B\$   |
| 2025-11-05   | 1.25 | 16.66 B\$   |

**Analysis:**
The two most recent quarterly EPS values are higher than the rest. And the most recent quarterly revenue value is higher than the rest.

**6) Financial Information**

Revenue and Profitability:

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-09-30   | \$17.28B   | 77.69%        |
| 2025-06-30   | \$15.81B   | 77.50%        |
| 2025-03-31   | \$15.53B   | 77.98%        |
| 2024-12-31   | \$15.62B   | 75.50%        |
| 2024-09-30   | \$16.66B   | 75.51%        |

Capital and Profitability:

| Quarter      | Equity     | ROE   |
|--------------|------------|-------|
| 2025-09-30   | \$51.85B   | 11.16% |
| 2025-06-30   | \$48.99B   | 9.04%  |
| 2025-03-31   | \$48.34B   | 10.51% |
| 2024-12-31   | \$46.31B   | 8.08%  |
| 2024-09-30   | \$44.50B   | 7.09%  |

**Analysis:**

*   **Revenue:** Revenue has generally increased over the last five quarters.
*   **Profit Margin:** The profit margin is consistently high, above 75%, indicating good cost control.
*   **Equity:** Equity is increasing, suggesting the company is building value.
*   **ROE:** ROE fluctuates, but generally shows improvement over the period. This indicates improved profitability on equity.

**7) Comprehensive Analysis**

*   **Mixed Signals:** MRK presents a mixed bag of investment signals. While the company has strong financials, a "Buy" consensus from analysts, and some positive news, its stock price has underperformed the broader market significantly.
*   **Technical Indicators:** The stock is in a short-term uptrend, but the RSI suggests it might be overbought.
*   **Key Considerations:**
    *   **Underperformance:** The substantial underperformance compared to the S&P 500 is a significant concern.
    *   **Long-Term Outlook:** The negative expected return (-29.1%) suggests potential challenges in the long term.
    *   **Overbought Conditions:** The high RSI indicates that a pullback may be coming.
    *   **News Sentiment:** The news is a mixed bag, making it difficult to gauge overall sentiment.
    *   **Analyst Targets:** Analyst price targets suggest some potential upside but should be considered in light of the other factors.
*   **Bottom Line:** The information suggests a cautious approach to MRK. While there are some positive factors, the underperformance and negative expected return warrant careful consideration of the risks involved.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.